RATIONALE: The monoclonal antibodytrastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances to them without harming normal cells. Biological therapies such as gefitinib may also interfere with the growth of tumor cells and may enhance the effects of trastuzumab. Combining trastuzumab with gefitinib may be an effective treatment for metastatic breast cancers with high amounts of HER2.

PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab with gefitinib in treating patients who have HER2-positive breast cancer.

Condition	Treatment or Intervention	Phase
stage IV breast cancer recurrent breast cancer Male Breast Cancer	Drug: gefitinib  Drug: trastuzumab  Procedure: antibody therapy  Procedure: biological response modifier therapy  Procedure: enzyme inhibitor therapy  Procedure: monoclonal antibody therapy  Procedure: protein tyrosine kinase inhibitor therapy	Phase II

Further Study Details: 

OBJECTIVES:

• Determine the response rate, duration of response, and time to progression in patients with metastatic breast cancer that overexpresses HER2-neu treated with trastuzumab (Herceptin) and gefitinib .
• Determine the phase II dose of gefitinib when given in combination with trastuzumab in these patients.
• Determine the toxicity of this regimen in these patients.
• Determine the 3- and 6-month progression-free survival of patients treated with this regimen.
• Correlate response rates with plasma levels of circulating HER2 and tumor levels of epidermal growth factor receptor, activated HER2, and HER2 receptors, as measured by immunohistochemistry and/or fluorescent in situ hybridization (FISH), in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of gefitinib. The phase I portion of this study was open in only 5 ECOG institutions. The phase I portion has been completed, and the study is being opened in all ECOG-affiliated institutions.

• Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1. Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.
• Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 3-12 patients will be accrued for the phase I portion of this study. The phase I portion of this study has been completed. A total of 34-132 patients (15-46 previously treated with chemotherapy but not trastuzumab [Herceptin] in the metastatic setting; 19-86 not previously treated with chemotherapy or trastuzumab in the metastatic setting) will be accrued for the phase II portion of this study.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic adenocarcinoma of the breast
• Patients may have had or not had standard first-line chemotherapy for the treatment of metastatic disease
• Overexpression of HER2-neu (HER2 3+ by immunohistochemistry or gene amplification as measured by fluorescent in situ hybridization)
• Measurable disease
• Patients with no prior adjuvant chemotherapy may have failed or not failed first-line chemotherapy for metastatic disease
• No more than 2 prior systemic chemotherapy regimens for metastatic disease
• Relapse while receiving or within 6 months of completion of adjuvant chemotherapy is considered failure of 1 regimen for metastatic disease
• No untreated brain metastases or brain metastases undergoing radiotherapy
• Previously treated brain metastasis that has responded to radiotherapy and/or surgery allowed if not sole site of measurable disease
• Hormone receptor status:
• Not specified

PATIENT CHARACTERISTICS: Age:

• 18 and over

Sex:

• Male or female

Menopausal status:

• Not specified

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Granulocyte count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3

Hepatic:

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST and ALT no greater than 3 times ULN (5 times ULN if liver metastases is present)
• INR no greater than 1.5 times ULN
• PT and PTT no greater than 1.5 times ULN

Renal:

• Creatinine no greater than 1.5 mg/dL
• No more than trace blood or protein in urine

Cardiovascular:

• LVEF at least 50% by MUGA scan
• No prior New York Heart Association class I-IV heart disease
• No PR prolongation or atrioventricular block on ECG

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception (preferably nonhormonal)
• Random blood sugar less than 2.5 times ULN
• No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No other acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation

PRIOR CONCURRENT THERAPY: Biologic therapy:

• No prior trastuzumab (Herceptin)
• No other concurrent immunologic therapy

Chemotherapy:

• See Disease Characteristics
• No prior cumulative dose of doxorubicin more than 360 mg/m^2
• No concurrent chemotherapy

Endocrine therapy:

• At least 2 weeks since prior hormonal therapy
• No concurrent hormonal therapy, including tamoxifen
• No concurrent dexamethasone, progesterone, or glucocorticoids

Radiotherapy:

• See Disease Characteristics
• At least 2 weeks since prior radiotherapy
• No prior radiotherapy to target lesions or only site of measurable disease
• No concurrent radiotherapy

Surgery:

• See Disease Characteristics
• No prior organ allograft

Other:

• No prior gefitinib
• No prior immunosuppressive therapy
• At least 2 weeks since prior cytotoxic drugs
• No concurrent carbamazepine, ethosuximide, griseofulvin, nafcillin, nelfinavir mesylate, nevirapine, oxcarbazepine, phenobarbital, phenylbutazone, phenytoin, primidone, rifabutin, rifampin, rofecoxib, Hypericum perforatum (St. John's Wort), sulfadimidine, sulfinpyrazone, or troglitazone
• No other concurrent investigational agents
• No concurrent topical eye agents
• Concurrent bisphosphonates allowed for hypercalcemia and/or prophylaxis of bone metastases

Alabama
      University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham,  Alabama,  35294-3300,  United States
Colorado
      CCOP - Colorado Cancer Research Program, Incorporated, Denver,  Colorado,  80224,  United States
Florida
      H. Lee Moffitt Cancer Center and Research Institute, Tampa,  Florida,  33612-9497,  United States
Illinois
      CCOP - Carle Cancer Center, Urbana,  Illinois,  61801,  United States
      CCOP - Evanston, Evanston,  Illinois,  60201,  United States
      Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago,  Illinois,  60611,  United States
Indiana
      CCOP - Northern Indiana CR Consortium, South Bend,  Indiana,  46601,  United States
      Indiana University Cancer Center, Indianapolis,  Indiana,  46202-5289,  United States
Louisiana
      CCOP - Ochsner, New Orleans,  Louisiana,  70121,  United States
      MBCCOP - LSU Health Sciences Center, New Orleans,  Louisiana,  70112,  United States
Maryland
      Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore,  Maryland,  21231,  United States
Massachusetts
      Tufts - New England Medical Center, Boston,  Massachusetts,  02111,  United States
Michigan
      CCOP - Kalamazoo, Kalamazoo,  Michigan,  49007-3731,  United States
Minnesota
      CCOP - Duluth, Duluth,  Minnesota,  55805,  United States
      CCOP - Metro-Minnesota, Saint Louis Park,  Minnesota,  55416,  United States
New York
      Albert Einstein Clinical Cancer Center, Bronx,  New York,  10461,  United States
      MBCCOP-Our Lady of Mercy Cancer Center, Bronx,  New York,  10466,  United States
      NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York,  New York,  10016,  United States
Oklahoma
      CCOP - Oklahoma, Tulsa,  Oklahoma,  74136,  United States
Pennsylvania
      CCOP - Geisinger Clinic and Medical Center, Danville,  Pennsylvania,  17822-2001,  United States
      CCOP - MainLine Health, Wynnewood,  Pennsylvania,  19096,  United States
      Fox Chase Cancer Center, Philadelphia,  Pennsylvania,  19111-2497,  United States
      Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey,  Pennsylvania,  17033-0850,  United States
Tennessee
      Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville,  Tennessee,  37232-6307,  United States
Texas
      CCOP - Scott and White Hospital, Temple,  Texas,  76508,  United States
Wisconsin
      CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay,  Wisconsin,  54307-3453,  United States
      University of Wisconsin Comprehensive Cancer Center, Madison,  Wisconsin,  53792-0001,  United States
Peru
      Instituto de Enfermedades Neoplasicas, Lima,  34,  Peru

Study chairs or principal investigators

Carlos L. Arteaga, MD,  Study Chair,  Vanderbilt-Ingram Cancer Center   

Study ID Numbers:  CDR0000068896; ECOG-1100
Record last reviewed:  February 2005
Last Updated:  February 8, 2005
Record first received:  September 13, 2001
ClinicalTrials.gov Identifier:  NCT00024154
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2005-04-08